Impact of My Dose Coach App Frequency of Use on Clinical Outcomes in Type 2 Diabetes.
Glycemic control
Mobile application
Self-management
Type 2 diabetes mellitus
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
22
12
2021
accepted:
28
02
2022
pubmed:
23
3
2022
medline:
23
3
2022
entrez:
22
3
2022
Statut:
ppublish
Résumé
My Dose Coach (MDC) is a US Food and Drug Administration-approved digital smartphone application designed to help users with type 2 diabetes (T2D) titrate their basal insulin (BI) according to a clinician-prescribed individualized titration plan. The aim of this analysis was to assess the impact of the frequency of MDC use on clinical outcomes. This retrospective observational analysis included people with T2D who were registered for MDC (August 1st, 2018-April 30th, 2020) and received BI. Users with an activated care plan and ≥2 fasting blood glucose (FBG) observations spanning ≥2 weeks were defined as active. Outcomes included percentage achieving their individual FBG target, time to FBG target, change in FBG, change in insulin dose and hypoglycemia. Users were stratified into high (>3 days per week), moderate (>1- ≤3 days per week), and low (≤1 day per week) MDC usage groups. The analysis included 2517 active MDC users. Approximately 49% of users had high MDC usage. Overall, 44% of users across all usage frequencies achieved their individual FBG target. High MDC use was associated with significantly better FBG target achievement and less time to FBG target versus moderate- and low-usage groups (p≤0.01 for all). Insulin dose change was significantly greater in the high- versus moderate-usage group (p=0.01). There was no significant difference in hypoglycemia incidence among MDC usage groups (12%-16% of users in any usage group). More frequent MDC usage was associated with better FBG outcomes without increased hypoglycemia risk.
Identifiants
pubmed: 35316509
doi: 10.1007/s13300-022-01245-9
pii: 10.1007/s13300-022-01245-9
pmc: PMC8938735
doi:
Types de publication
Journal Article
Langues
eng
Pagination
983-993Informations de copyright
© 2022. The Author(s).
Références
Diabetes Care. 2019 Mar;42(3):416-426
pubmed: 30104301
Diabetes Care. 2021 Jan;44(Suppl 1):S73-S84
pubmed: 33298417
Cochrane Database Syst Rev. 2014 Sep 04;(9):CD006424
pubmed: 25188210
Diabetes Spectr. 2018 Aug;31(3):279-287
pubmed: 30140145
Diabetes Metab Res Rev. 2021 Sep;37(6):e3418
pubmed: 33098260
Patient Educ Couns. 2004 Jan;52(1):97-105
pubmed: 14729296
Diabetes Obes Metab. 2018 Mar;20(3):488-496
pubmed: 29053215
Diabetes Obes Metab. 2021 Aug;23(8):1722-1732
pubmed: 33950566
PLoS One. 2017 Jan 3;12(1):e0168835
pubmed: 28045979
BMJ Health Care Inform. 2019 Oct;26(1):
pubmed: 31676495
Diabetes Obes Metab. 2019 Oct;21(10):2327-2332
pubmed: 31173451
Diabetes Obes Metab. 2017 Aug;19(8):1155-1164
pubmed: 28251792
Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S432-3
pubmed: 23565455
Diabetes Spectr. 2019 May;32(2):104-111
pubmed: 31168280
Diabetes Obes Metab. 2018 Feb;20(2):427-437
pubmed: 28834075
Diabetes Technol Ther. 2021 Mar;23(S1):S15-S20
pubmed: 33449822
Diabetes Obes Metab. 2018 Feb;20(2):301-308
pubmed: 28719066
Diabetes Metab Syndr Obes. 2020 Apr 23;13:1327-1338
pubmed: 32368124
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1109-1120
pubmed: 32659694